Literature DB >> 35318511

Diabetic Kidney Disease: From Pathogenesis to Novel Treatment Possibilities.

Ara Aboolian1, Sofia Urner1, Michael Roden2,1,3, Jay Chandra Jha4, Karin Jandeleit-Dahm5,6.   

Abstract

One of the microvascular complications of diabetes is diabetic kidney disease (DKD), often leading to end stage renal disease (ESRD) in which patients require costly dialysis or transplantation. The silent onset and irreversible progression of DKD are characterized by a steady decline of the estimated glomerular filtration rate, with or without concomitant albuminuria. The diabetic milieu allows the complex pathophysiology of DKD to enter a vicious cycle by inducing the synthesis of excessive amounts of reactive oxygen species (ROS) causing oxidative stress, inflammation, and fibrosis. As no cure is available, intensive research is required to develop novel treatments possibilities. This chapter provides an overview of the important pathomechanisms identified in diabetic kidney disease, the currently established therapies, as well as recently developed novel therapeutic strategies in DKD.
© 2022. The Author(s), under exclusive license to Springer Nature Switzerland AG.

Entities:  

Keywords:  Diabetic kidney disease; Diabetic nephropathy; Fibrosis; Inflammation; NADPH oxidase; Oxidative stress

Mesh:

Year:  2022        PMID: 35318511     DOI: 10.1007/164_2021_576

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  185 in total

1.  The receptor for advanced glycation endproducts mediates podocyte heparanase expression through NF-κB signaling pathway.

Authors:  Xiaofei An; Lin Zhang; Qiuming Yao; Ling Li; Bin Wang; Jisheng Zhang; Ming He; Jinan Zhang
Journal:  Mol Cell Endocrinol       Date:  2017-05-04       Impact factor: 4.102

Review 2.  Evolution of NADPH Oxidase Inhibitors: Selectivity and Mechanisms for Target Engagement.

Authors:  Sebastian Altenhöfer; Kim A Radermacher; Pamela W M Kleikers; Kirstin Wingler; Harald H H W Schmidt
Journal:  Antioxid Redox Signal       Date:  2014-02-26       Impact factor: 8.401

3.  Effects of NADPH oxidase inhibitor in diabetic nephropathy.

Authors:  Kensuke Asaba; Akihiro Tojo; Maristela Lika Onozato; Atsuo Goto; Mark T Quinn; Toshiro Fujita; Christopher S Wilcox
Journal:  Kidney Int       Date:  2005-05       Impact factor: 10.612

4.  Effects of Allopurinol on the Progression of Chronic Kidney Disease.

Authors:  Sunil V Badve; Elaine M Pascoe; Anushree Tiku; Neil Boudville; Fiona G Brown; Alan Cass; Philip Clarke; Nicola Dalbeth; Richard O Day; Janak R de Zoysa; Bettina Douglas; Randall Faull; David C Harris; Carmel M Hawley; Graham R D Jones; John Kanellis; Suetonia C Palmer; Vlado Perkovic; Gopala K Rangan; Donna Reidlinger; Laura Robison; Robert J Walker; Giles Walters; David W Johnson
Journal:  N Engl J Med       Date:  2020-06-25       Impact factor: 91.245

Review 5.  The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology.

Authors:  Karen Bedard; Karl-Heinz Krause
Journal:  Physiol Rev       Date:  2007-01       Impact factor: 37.312

6.  Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine.

Authors:  Roya Babaei-Jadidi; Nikolaos Karachalias; Naila Ahmed; Sinan Battah; Paul J Thornalley
Journal:  Diabetes       Date:  2003-08       Impact factor: 9.461

Review 7.  Keap1/Nrf2/ARE signaling unfolds therapeutic targets for redox imbalanced-mediated diseases and diabetic nephropathy.

Authors:  Temitope Isaac Adelusi; Lei Du; Meng Hao; Xueyan Zhou; Qian Xuan; Chowdhury Apu; Ying Sun; Qian Lu; Xiaoxing Yin
Journal:  Biomed Pharmacother       Date:  2020-01-13       Impact factor: 6.529

8.  Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.

Authors:  George L Bakris; Rajiv Agarwal; Stefan D Anker; Bertram Pitt; Luis M Ruilope; Peter Rossing; Peter Kolkhof; Christina Nowack; Patrick Schloemer; Amer Joseph; Gerasimos Filippatos
Journal:  N Engl J Med       Date:  2020-10-23       Impact factor: 91.245

9.  A Randomized Controlled Trial of the Effects of Febuxostat Therapy on Adipokines and Markers of Kidney Fibrosis in Asymptomatic Hyperuricemic Patients With Diabetic Nephropathy.

Authors:  Srinivasan Beddhu; Rebecca Filipowicz; Bin Wang; Guo Wei; Xiaorui Chen; Abinash C Roy; Scott L DuVall; Hanadi Farrukh; Arsalan N Habib; Terrence Bjordahl; Debra L Simmons; Mark Munger; Greg Stoddard; Donald E Kohan; Tom Greene; Yufeng Huang
Journal:  Can J Kidney Health Dis       Date:  2016-12-05

10.  Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy.

Authors:  Celine C Berthier; Hongyu Zhang; MaryLee Schin; Anna Henger; Robert G Nelson; Berne Yee; Anissa Boucherot; Matthias A Neusser; Clemens D Cohen; Christin Carter-Su; Lawrence S Argetsinger; Maria P Rastaldi; Frank C Brosius; Matthias Kretzler
Journal:  Diabetes       Date:  2008-11-18       Impact factor: 9.461

View more
  1 in total

Review 1.  Molecular Mechanistic Pathways Targeted by Natural Compounds in the Prevention and Treatment of Diabetic Kidney Disease.

Authors:  Kaixuan Zhou; Xue Zi; Jiayu Song; Qiulu Zhao; Jia Liu; Huiwei Bao; Lijing Li
Journal:  Molecules       Date:  2022-09-21       Impact factor: 4.927

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.